Best Available Copy

02:53pm From-Novartis V&D IP Dept 510-923-3542

T-280 P.003/003

PART B - FEE(S) TRANSMITTAL

together with applicable fee(s), to: Mail Mail Stop ISSUE FEE



INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 5 should be completed appropriate, All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address; and/or (b) indicating a separate FEE ADDRES indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate FEE ADDRES maintenance fee notifications. (I MRANT CORRUSPUNDENCE AIDMESS (Notice Use black 1 for any change of address) 17-176. The Organization of the Correspondence address, and/or (b) indicating a separate FEE ADDRESS maintenance fee notification. NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY- X100B P.O. BOX 8097 Emeryville, CA 94662-8097 Emeryville, CA 94662-8097 APPLICATION NO. FILLING DATE FIRST NAMED INVENTOR APPLICATION EE MODISIENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER APPLN TYPE SMALL ENTITY ISSUE FEE DATE PUBLICATION FEE DUE PREV PAID ISSUE FEE IOTAL FEE(5) DUE DATE DUE NO 5/24/2010 DATE DUE NO 5/24/2010 APPLN TYPE SMALL ENTITY ISSUE FEE DATE PUBLICATION FEE DUE PREV PAID ISSUE FEE IOTAL FEE(5) DUE DATE DUE NO 5/24/2010 DATE DUE NO 5/24/2010 DATE DUE NO 5/24/2010 SO 5/24/2010
Note: A certificate cannot be used for any change of address) 17476 7590 02/24/2010 NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY- X100B P.O. BOX 8097 Emeryville, CA 94662-8097 Emeryville, CA 94662-8097 Tansmitted to the USPTO (571) 273-2885, on the date indicated below. It is a sum as in a signment or formal drawing have its own certificate or mailing or transmission. It hereby certify that this Feels) Transmitted is being deposited with the Austries Postal Service with sufficient postage for first class mail in an entransmission of the Mail Stop ISSUE FEE address above, or being fuestion that is the property of the Mail Stop ISSUE FEE address above, or being fuestion to the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail of the USPTO (571) 273-2885, on the date indicated below. It is a mail
NOVARTIS VACCINES AND DIAGNOSTICS INC. INTELLECTUAL PROPERTY- X100B P.O. BOX 8097 Emeryville, CA 94662-8097 APPLICATION NO. FILING DATE PIRST NAMED INVENTOR APPLICATION NO. FILING DATE FIRST NAMED INVENTOR APPLICATION SETTION
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/016,604 12/07/2001 Pablo D. Garcia PP016466,0002 6543 FITLE OF INVENTION: ENDOCHENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER APPLN TYPE SMALL ENTITY ISSUE FEE DAIL PUBLICATION FEE DUE PREV PAID ISSUE FEE TOTAL FEE(5) DUE DATE DUE 05/24/2010
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/016,604 12/07/2001 Pablo D. Garcia PP016466,0002 6543 FITTLE OF INVENTION: ENDOCHENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER APPLN TYPE SMALL ENTITY ISSUE FEE DAIL PUBLICATION FEE DUE PREV PAID ISSUE FEE TOTAL FEE(5) DUE DATE DUE 05/24/2010
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/016,604 12/07/2001 Pablo D. Garcia PPO16466,0002 6543 FITLE OF INVENTION: ENDOCHENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER APPLN TYPE SMALL ENTITY ISSUE FEE DAIL PUBLICATION FEE DUE PREV PAID ISSUE FEE TOTAL FEE(5) DUE DATE DUE: 10/016,604 12/07/2001 Pablo D. Garcia PPO16466,0002 6543
10/016.604 12/07/2001 Pablo D. Garcia PPO16466.0002 6543 FITLE OF INVENTION: ENDOCHENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER APPLN TYPE SMALL ENTITY ISSUE FEE DAIL PUBLICATION FEE DUE PREV PAID ISSUE FEE TOTAL FEE(5) DUE DATE DUE 05/24/2010
TITLE OF INVENTION: ENDOSEROUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER APPLN TYPE SMALL ENTITY ISSUE: FEE DOIL PUBLICATION FEE DUE PREV PAID ISSUE FEE TOTAL FEE(5) DUE DATE DUE: OS. 24.70 UP 10.016.604 12.07.201 12.07.201 13.07.201 14.07.201 15.07.201 15.07.201 16.07.201 17.07.201
APPEN 1411
nonprovisional NO \$1510 \$0 \$0 \$1510 05/24/2010
EXAMINER ART UNIT CLASS-SUBCLASS
HUMPHREY, LOUISE WANG ZHIYING 1648 435-005000
I. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). I. Change of correspondence address (or Change of Correspondence Address form PTD/SB/122) attached. I. The contract of correspondence address (or Change of Correspondence Address form PTD/SB/122) attached. I. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the names of up to 3 registered patent attorneys or agents or agents of up to 2 registered attorney or agent, and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. If an assignce is identified below, the document has been fire recordation as set furth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)
Novartis Vaccines and Diagnostics, Inc. Emeryville, CA
Please check the appropriate assignce category or categories (will not be printed on the patent):
4a The following fee(s) are submitted: Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously paid issue fee shown above) Like Following fee(s): (Please first reapply any previously pa
AA-Advance Order - # of Copies overpayment, to Deposit Account Number 03-1664 (enclose an extra copy of this full
5. Change in Entity Status (from status indicated above) Li a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27 Lib. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).
5. Change in Entity Status (from status indicated above)
5. Change in Enrity Status (from status indicated above) L. a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27 [L. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). MANY CR. 1. See and Publication For IT counted will not be accounted from anyone other than the applicant; a registered attorney or agent; or the assignee or other plan.

This collection of information is required by 37 CFR 1.31. The information is required to obtain or retain a benefit by the public which is to like (and by the USFTO to page 45) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing an application to the USFTO. Time will very depending upon the individual case. Any comments on the amount of time you require to collected this form under suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Communed 37 O. Hostington and Trademark Office, U.S. Department of Communed 37 O. Revandria, Virginia 22313-1450. DO NOT SEND FELS OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Bostington Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number